Protagonist Therapeutics (PTGX) Stock Price, Quote, News & History | Benzinga

SPY777.82−0.10%QQQ745.94−0.71%BTC/USD82,436.80−1.48%DIA517.95+0.36%GLD382.24−0.61%TLT77.97−0.02%

Protagonist Therapeutics Inc (PTGX) Stock Price, Quote, News & History

PTGXNASDAQ

Trade with Public

Trade with Public

$144.37

0.640.45%

Last update: Oct 12, 1:51 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$145.83

Close

-

Volume / Avg.

528.24K / 640.23K

Day Range

$144.37 - $144.37

52 Wk Range

65.56 - 160.81

Market Cap

$9.30B

P/E Ratio

139.54

Dividend Yield

-

Exchange

NASDAQ

RSI

54

Short Interest

16.78%

Days to Cover

11.49

Recent Protagonist Therapeutics, Inc. News

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised

Avi Kapoor

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.

Vandana Singh

Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.

Vandana Singh

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.

Avi Kapoor

This $300 Million Biotech May Be Deeply Mispriced: Analyst

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

131.20M

Investing Cash Flow (TTM)

78.72M

Financing Cash Flow (TTM)

41.61M

Free Cash Flow (TTM)

130.58M

Capital Expenditure (TTM)

-615.00K

Net Change in Cash (TTM)

251.53M

Analyst Trends and Forecast

2

Jul

8

Aug

2

Sep

2

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$8.53B

PE Ratio (TTM)

139.54

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

34.33

PB Ratio (TTM)

11.05

Earnings Yield % (TTM)

0.72%

Earnings Yield % (FWD)

-1.95%

EV / EBITDA (TTM)

142.40

Price / EBITDA (TTM)

161.68

Price / Free Cash Flow (TTM)

74.15

Book Value / Share

$13.01

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$420.08M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-